Antineoplastic Agents: Cytotoxic Agents: Antimetabolites
IGEMZ1 “Gemzar injection” 200 mg/vial
IGEMM1 “Gemmis injection” 38 mg/ml; 30ml/vial
IGEMM2 “Gemmis injection” 38 mg/ml; 6ml/vial
適應症：1.非小細胞肺癌；2.胰臟癌；3.膀胱癌；4.Gemcitabine與paclitaxel併用，可使用於曾經使用過anthracycline之局部復發且無法手術切除或轉移性之乳癌患者；5.用於曾經使用含鉑類藥物（platinum-based）治療後復發且間隔至少6個月之卵巢癌，作為第二線治療。
Usual dose:
Bladder cancer: 1000 mg/m2 administered over 30- 60 min on days 1, 8, and 15; cisplatin 70 mg/m2 on Day-2.
Breast cancer: 1250 mg/m2 IV on Day-1 and Day-8 of each 21-day cycle, with paclitaxel 175 mg/m2 given as a 3-h infusion before gemcitabine on Day-1 of each 21-day cycle.
Lung cancer, non-small cell (3-wk schedule): 1250 mg/m2 IV Day-1 & Day-8 q21d; cisplatin 100 mg/m2 IV after gemcitabine on Day-1.
Lung cancer, non-small cell (4-wk schedule): 1000 mg/m2 IV Day-1, 8, & 15 q28d; cisplatin 100 mg/m2 IV after gemcitabine on Day-1.
Pancreatic cancer (initial cycle): 1000 mg/m2 IV weekly for 7 followed by 1 wk rest; (subsequent cycles): 1000 mg/m2 IV weekly for 3 then 1 wk rest.
Adverse effect:
Common: cutaneous reactions (rash, cellulitis), flu-like symptoms (fever, fatigue), nausea, vomiting, peripheral edema; proteinuria.
健保使用規範：（92/12/1、93/8/1、94/10/1、96/5/1、99/10/1、105/2/1）
限用於
1.晚期或無法手術切除之非小細胞肺癌及胰臟癌病患。
2.晚期膀胱癌病患。（92/12/1）
3.Gemcitabine與paclitaxel併用，可使用於曾經使用過anthracycline之局部復發且無法手術切除或轉移性之乳癌病患。（94/10/1）
4.用於曾經使用含鉑類藥物 (platinum-based) 治療後復發且間隔至少6個月之卵巢癌，作為第二線治療。（96/5/1、99/10/1）
5.無法手術切除或晚期或復發之膽道癌(含肝內膽管)病患。（105/2/1）